158 related articles for article (PubMed ID: 28406352)
1. Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
Liu H; Zhang J; Ren S; Chen M; Liu L; Zhang H
Leuk Lymphoma; 2017 Nov; 58(11):2758-2761. PubMed ID: 28406352
[No Abstract] [Full Text] [Related]
2. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
3. Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
Chen C; Xu W; Yang J
Leuk Lymphoma; 2015 Jan; 56(1):141-6. PubMed ID: 24724783
[TBL] [Abstract][Full Text] [Related]
4. CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.
Chen L; Yin Q; Mi R; Wei X
Leuk Lymphoma; 2013 Oct; 54(10):2291-3. PubMed ID: 23369043
[No Abstract] [Full Text] [Related]
5. Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia.
Fang B; Liu Y; Zhou J; Li Y; Song Y
Am J Hematol; 2012 Jan; 87(1):126-7. PubMed ID: 22072502
[No Abstract] [Full Text] [Related]
6. Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.
Wang FX; Zhang WG; He AL; Cao XM; Chen YX; Zhao WH; Yang Y; Wang JL; Zhang PY; Gu LF
Leuk Res; 2016 Sep; 48():57-61. PubMed ID: 27497340
[TBL] [Abstract][Full Text] [Related]
7. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
Gu LF; Zhang WG; Wang FX; Cao XM; Chen YX; He AL; Liu J; Ma XR
J Cancer Res Clin Oncol; 2011 Jun; 137(6):997-1003. PubMed ID: 21152934
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
Wu L; Li X; Su J; He Q; Zhang X; Chang C; Pu Q
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1563-9. PubMed ID: 21845438
[TBL] [Abstract][Full Text] [Related]
10. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
[TBL] [Abstract][Full Text] [Related]
11. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
Wang J; Lü S; Yang J; Song X; Chen L; Huang C; Hou J; Zhang W
J Hematol Oncol; 2009 Jul; 2():32. PubMed ID: 19642997
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Wu L; Li X; Chang C; Xu F; He Q; Wu D; Zhang Z; Su J; Zhou L; Song L; Chao X; Zhao Y
Leuk Lymphoma; 2016; 57(6):1367-74. PubMed ID: 26397697
[TBL] [Abstract][Full Text] [Related]
14. The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution.
Chen A; Yang J; Hu S; Wang QF
Sci China Life Sci; 2015 Dec; 58(12):1302-5. PubMed ID: 26588914
[No Abstract] [Full Text] [Related]
15. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
[TBL] [Abstract][Full Text] [Related]
16. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
18. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
[TBL] [Abstract][Full Text] [Related]
20. A homoharringtonine-based regimen for childhood acute myelogenous leukemia.
Tang J; Xue H; Pan C; Chen J; Gu L; Zhao H
Med Pediatr Oncol; 2003 Jul; 41(1):70-2. PubMed ID: 12764750
[No Abstract] [Full Text] [Related]
[Next] [New Search]